Women May Feel Psychedelics More Strongly Than Men—Scientists Don’t Yet Know Why

As psychedelic therapy moves toward mainstream medicine, a critical question is emerging: do men and women respond differently to these powerful compounds? A growing body of research suggests that women may experience the effects of psychedelic drugs—such as LSD, psilocybin, and MDMA—more intensely than men, even at the same dose. The reasons remain unclear, but scientists are investigating biological, hormonal, and social factors that could explain the gender gap. This matters because psychedelic-assisted treatments for depression, PTSD, and anxiety are being developed now, and dosing protocols may need to account for sex-based differences to ensure safety and efficacy. Without understanding these variations, clinical trials risk underdosing or overdosing half the population. Researchers are calling for more inclusive studies that track menstrual cycles, hormonal contraceptives, and body composition. As the field races toward FDA approval, closing this knowledge gap is not just a scientific curiosity—it’s a patient safety issue. The next wave of psychedelic research must include women in meaningful numbers, or we risk building a mental health revolution that only works for half of humanity.